Log in / Register
Home arrow Environment arrow Inflammatory Disorders of the Nervous System: Pathogenesis, Immunology, and Clinical Management


  • 1. Hellmuth J, Fletcher JL, Valcour V, Kroon E, Ananworanich J, Intasan J, Lerdlum S, Narvid J, Pothisri M, Allen I, Krebs SJ, Slike B, Prueksakaew P, Jagodzinski LL, Puttamaswin S, Phanuphak N, Spudich S, SEARCH 010/RV254 Study Group. Neurologic signs and symptoms frequently manifest in acute HIV infection. Neurology. 2016;87(2):148-54.
  • 2. Brannagan 3rd TH, Zhou Y. HIV-associated Guillain-Barre syndrome. J Neurol Sci. 2003;208(1-2):39-42.
  • 3. Denning DW, Anderson J, Rudge P, Smith H. Acute myelopathy associated with primary infection with human immunodeficiency virus. Br Med J (Clin Res Ed). 1987;294(6565):143-4.
  • 4. Reus S, Boix V, Priego M, Merino E, Portilla J. Cytomegalovirus polyradiculopathy presenting as bilateral radial nerve palsies in a patient with AIDS. Eur J Clin Microbiol Infect Dis. 1999;18(8):605-6.
  • 5. Carroll MB, Holmes R. Dermatomyositis and HIV infection: case report and review of the literature. Rheumatol Int. 2011;31(5):673-9.
  • 6. Johnson RW, Williams FM, Kazi S, Dimachkie MM, Reveille JD. Human immunodeficiency virus-associated polymyositis: a longitudinal study of outcome. Arthritis Rheum. 2003;49(2):172-8.
  • 7. Chariot P, Ruet E, Authier FJ, Levy Y, Gherardi R. Acute rhabdomyolysis in patients infected by human immunodeficiency virus. Neurology. 1994;44(9):1692-6.
  • 8. Nath A. Neurologic complications of human immunodeficiency virus infection. Continuum (Minneap Minn). 2015;21(6 Neuroinfectious Disease):1557-76.
  • 9. Couderc LJ, D’Agay MF, Danon F, et al. Sicca complex and infection with human immunodeficiency virus. Arch Intern Med. 1987;147:898-901.
  • 10. Teener JW. Inflammatory and toxic myopathy. Semin Neurol. 2012;32(5):491-9. doi:10.105 5/s-0033-1334467. Epub 2013 May 15.
  • 11. Kiyomoto BH, Tengan CH, Godinho RO. Effects of short-term zidovudine exposure on mitochondrial DNA content and succinate dehydrogenase activity of rat skeletal muscle cells. J Neurol Sci. 2008;268(1-2):33-9.
  • 12. Sacktor N, Skolasky RL, Ernst T, Mao X, Selnes O, Pomper MG, Chang L, Zhong K, Shungu DC, Marder K, Shibata D, Schifitto G, Bobo L, Barker PB. A multicenter study of two magnetic resonance spectroscopy techniques in individuals with HIV dementia. J Magn Reson Imaging. 2005;21(4):325-33.
  • 13. Petito CK, Navia BA, Cho ES, Jordan BD, George DC, Price RW. Vacuolar myelopathy pathologically resembling subacute combined degeneration in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1985;312(14):874-9.
  • 14. Henin D, Smith TW, De Girolami U, Sughayer M, Hauw JJ. Neuropathology of the spinal cord in the acquired immunodeficiency syndrome. Hum Pathol. 1992;23(10):1106-14.
  • 15. Moulignier A, Moulonguet A, Pialoux G, Rozenbaum W. Reversible ALS-like disorder in HIV infection. Neurology. 2001;57(6):995-1001.
  • 16. Ortiz G, Koch S, Romano JG, Forteza AM, Rabinstein AA. Mechanisms of ischemic stroke in HIV-infected patients. Neurology. 2007;68(16):1257-61.
  • 17. Minagar A, Schatz NJ, Glaser JS. Case report: one-and-a-half-syndrome and tuberculosis of the pons in a patient with AIDS. AIDS Patient Care STDS. 2000;14(9):461-4.
  • 18. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White Jr AC, Hamill RJ. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS. 2005;19(4):399-406.
  • 19. Zaffiri L, Verma R, Struzzieri K, Monterroso J, Batts DH, Loehrke ME. Immune reconstitution inflammatory syndrome involving the central nervous system in a patient with HIV infection: a case report and review of literature. New Microbiol. 2013;36(1):89-92.
  • 20. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789-99.
  • 21. Gannon P, Khan MZ, Kolson DL. Current understanding of HIV-associated neurocognitive disorders pathogenesis. Curr Opin Neurol. 2011;24(3):275-83.
  • 22. Saylor D, Dickens AM, Sacktor N, Haughey N, Slusher B, Pletnikov M, Mankowski JL, Brown A, Volsky DJ, McArthur JC. HIV-associated neurocognitive disorder - pathogenesis and prospects for treatment. Nat Rev Neurol. 2016;12(5):309.
  • 23. Thompson PM, Dutton RA, Hayashi KM, Toga AW, Lopez OL, Aizenstein HJ, Becker JT. Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline. Proc Natl Acad Sci U S A. 2005;102(43):15647-52.
  • 24. Kirkland KE, Kirkland K, Many WJ, et al. Headache among patients with HIV disease: prevalence, characteristics, and associations. Headache. 2012;52:455-66.
  • 25. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629-808.
  • 26. Lipton RB, Feraru ER, Weiss G, et al. Headache in HIV-1-related disorders. Headache. 1991;31:518-22.
  • 27. Evers S, Wibbeke B, Tichelt D, et al. The impact of HIV infection on primary headache. Unexpected findings from retrospective, cross-sectional, and prospective analyses. Pain. 2000;85:191-200.
  • 28. Joshi SG, Cho TA. Pathophysiological mechanisms of headache in HIV. Headache. 2014;54:946-50.
  • 29. Sheikh HU, Cho TA. Clinical aspects of headache in HIV. Headache. 2014;54:939-45.
  • 30. Wu J, Wu H, Lu C, Guo L, Li P. Self-reported sleep disturbances in HIV-infected people: a meta-analysis of prevalence and moderators. Sleep Med. 2015;16(8):901-7.
  • 31. Norman SE, Resnick L, Cohn MA, et al. Sleep disturbances in HIV-seropositive patients. JAMA. 1988;260:922.
  • 32. Hand GA, Phillips KD, Dudgeon WD. Perceived stress in HIV-infected individuals: physiological and psychological correlates. AIDS Care. 2006;18:1011-7.
  • 33. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28:445-9.
  • 34. Robbins JL, Phillips KD, Dudgeon WD, et al. Physiological and psychological correlates of sleep in HIV infection. Clin Nurs Res. 2004;13:33-52.
  • 35. Phillips KD, Mock KS, Bopp CM, et al. Spiritual well-being, sleep disturbance, and mental and physical health status in HIV-infected individuals. Issues Ment Health Nurs. 2006;27:125-39.
  • 36. Reid S, Dwyer J. Insomnia in HIV infection: a systematic review of prevalence, correlates, and management. Psychosom Med. 2005;67:260-9.
  • 37. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA. 1989;262:1479-84.
  • 38. Ram S, Seirawan H, Kumar SK, et al. Prevalence and impact of sleep disorders and sleep habits in the United States. Sleep Breath. 2010;14:63-70.
  • 39. Vosvick M, Gore-Felton C, Ashton E, et al. Sleep disturbances among HIV-positive adults: the role of pain, stress, and social support. J Psychosom Res. 2004;57:459-63.
  • 40. Omonuwa TS, Goforth HW, Preud’homme X, et al. The pharmacologic management of insomnia in patients with HIV. J Clin Sleep Med. 2009;5:251-62.
  • 41. Wiegand M, Moller AA, Schreiber W, et al. Alterations of nocturnal sleep in patients with HIV infection. Acta Neurol Scand. 1991;83:141-2.
  • 42. Phillips KD, Sowell RL, Rojas M, et al. Physiological and psychological correlates of fatigue in HIV disease. Biol Res Nurs. 2004;6:59-74.
  • 43. Phillips KD, Sowell RL, Boyd M, et al. Sleep quality and health-related quality of life in HIV- infected African-American women of childbearing age. Qual Life Res. 2005;14:959-70.
  • 44. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005;143:714-21.
  • 45. Phillips KD, Moneyham L, Murdaugh C, et al. Sleep disturbance and depression as barriers to adherence. Clin Nurs Res. 2005;14:273-93.
  • 46. Gifford AL, Bormann JE, Shively MJ, et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23:386-95.
  • 47. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
  • 48. Jong E, Oudhoff LA, Epskamp C, Wagener MN, van Duijn M, Fischer S, van Gorp EC. Predictors and treatment strategies of HIV-related fatigue in the combined antiretroviral therapy era. AIDS. 2010;24(10):1387-405.
  • 49. Millikin CP, Rourke SB, Halman MH, Power C. Fatigue in HIV/AIDS is associated with depression and subjective neurocognitive complaints but not neuropsychological functioning. J Clin Exp Neuropsychol. 2003;25(2):201-15.
  • 50. Lee KA, Gay C, Portillo CJ, Coggins T, Davis H, Pullinger CR, Aouizerat BE. Symptom experience in HIV-infected adults: a function of demographic and clinical characteristics. J Pain Symptom Manage. 2009;38(6):882-93.
  • 51. Aouizerat BE, Gay CL, Lerdal A, Portillo CJ, Lee KA. Lack of energy: an important and distinct component of HIV-related fatigue and daytime function. J Pain Symptom Manage. 2013;45(2):191-201.
  • 52. Byun E, Gay CL, Lee KA. Sleep, fatigue, and problems with cognitive function in adults living with HIV. J Assoc Nurses AIDS Care. 2016;27(1):5-16.
  • 53. Tello-Velasquez JR, Diaz-Llanes BE, Mezones-Holgum E, Rodnguez-Morales AJ, Huamanr C, Hernandez AV, Arevalo-Abanto J. Poor quality of sleep associated with low adherence to highly active antiretroviral therapy in Peruvian patients with HIV/AIDS. Cad Saude Publica. 2015;31(5):989-1002.
  • 54. Low Y, Goforth H, Preud’homme X, Edinger J, Krystal A. Insomnia in HIV-infected patients: pathophysiologic implications. AIDS Rev. 2014;16(1):3-13.
  • 55. Norman SE, Chediak AD, Freeman C, et al. Sleep disturbances in men with asymptomatic human immunodeficiency (HIV) infection. Sleep. 1992;15:150-5.
  • 56. Darko DF, Mitler MM, White JL. Sleep disturbance in early HIV infection. Focus. 1995;10:5-6.
  • 57. Darko DF, Miller JC, Gallen C, White J, Koziol J, et al. Sleep electroencephalogram delta- frequency amplitude, night plasma levels of tumor necrosis factor alpha, and human immunodeficiency virus infection. Proc Natl Acad Sci U S A. 1995;92:12080-4.
  • 58. Chang FC, Opp MR. IL-1 is a mediator of increases in slow-wave sleep induced by CRH receptor blockade. Am J Physiol Regul Integr Comp Physiol. 2000;279:R793-802.
  • 59. Terao A, Matsumura H, Yoneda H, Saito M. Enhancement of slow-wave sleep by tumor necrosis factor-alpha is mediated by cyclooxygenase-2 in rats. Neuroreport. 1998;9: 3791-6.
  • 60. Takahashi S, Kapas L, Fang J, Krueger JM. Somnogenic relationships between tumor necrosis factor and interleukin-1. Am J Physiol. 1999;276:R1132-40.
  • 61. Gemma C, Opp MR. Human immunodeficiency virus glycoproteins 160 and 41 alter sleep and brain temperature of rats. J Neuroimmunol. 1999;97:94-101.
  • 62. Patil SP, Brown TT, Jacobson LP, Margolick JB, Laffan A, Johnson-Hill L, Godfrey R, Johnson J, Reynolds S, Schwartz AR, Smith PL. Sleep disordered breathing, fatigue, and sleepiness in HIV-infected and -uninfected men. PLoS One. 2014;9(7):e99258.
  • 63. Kunisaki KM, Akgun KM, Fiellin DA, Gibert CL, Kim JW, Rimland D, Rodriguez-Barradas MC, Yaggi HK, Crothers K. Prevalence and correlates of obstructive sleep apnoea among patients with and without HIV infection. HIV Med. 2015;16(2):105-13.
  • 64. Leung VL, Glesby MJ. Pathogenesis and treatment of HIV lipohypertrophy. Curr Opin Infect Dis. 2011;24:43-9.
  • 65. Saboisky JP, Stashuk DW, Hamilton-Wright A, Carusona AL, Campana LM, Trinder J, Eckert DJ, Jordan AS, McSharry DG, White DP, Nandedkar S, David WS, Malhotra A. Neurogenic changes in the upper airway of patients with obstructive sleep apnea. Am J Respir Crit Care Med. 2012;185:322-9.
  • 66. Nguyen AT, Jobin V, Payne R, Beauregard J, Naor N, Kimoff RJ. Laryngeal and velopharyngeal sensory impairment in obstructive sleep apnea. Sleep. 2005;28:585-93.
  • 67. Darquenne C, Hicks CB, Malhotra A. The ongoing need for good physiological investigation: obstructive sleep apnea in HIV patients as a paradigm. J Appl Physiol (1985). 2015;118(2):244-6.
  • 68. Lakey W, Yang LY, Yancy W, Chow SC, Hicks C. Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. AIDS Res Hum Retroviruses. 2013;29:435-40.
  • 69. Shapiro SD, Chin CH, Kirkness JP, McGinley BM, Patil SP, Polotsky VY, Biselli PJC, Smith PL, Schneider H, Schwartz AR. Leptin and the control of pharyngeal patency during sleep in severe obesity. J Appl Physiol. 2014;116:1334-41.
  • 70. Guilleminault C, Stoohs R, Clerk A, Cetel M, Maistros P. A cause of excessive daytime sleepiness. The upper airway resistance syndrome. Chest. 1993;104:781-7.
  • 71. Stepanski E, Lamphere J, Badia P, Zorick F, Roth T. Sleep fragmentation and daytime sleepiness. Sleep. 1984;7:18-26.
  • 72. Stepanski EJ. The effect of sleep fragmentation on daytime function. Sleep. 2002;25:268-76.
  • 73. Guilleminault C, Hagen CC, Huynh NT. Comparison of hypopnea definitions in lean patients with known obstructive sleep apnea hypopnea syndrome (OSAHS). Sleep Breath. 2009;13:341-7.
  • 74. Goswami U, Baker JV, Wang Q, Khalil W, Kunisaki KM. Sleep apnea symptoms as a predictor of fatigue in an urban HIV Clinic. AIDS Patient Care STDS. 2015;29(11):591-6.
  • 75. Navia BA, Cho ES, Petito CK, Price RW. The AIDS dementia complex: II. Neuropathology. Ann Neurol. 1986;19(6):525-35.
  • 76. Glass JD, Fedor H, Wesselingh SL, McArthur JC. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol. 1995;38(5):755-62.
  • 77. Masliah E, Ge N, Achim CL, Hansen LA, Wiley CA. Selective neuronal vulnerability in HIV encephalitis. J Neuropathol Exp Neurol. 1992;51(6):585-93.
  • 78. Everall IP, Glass JD, McArthur J, Spargo E, Lantos P. Neuronal density in the superior frontal and temporal gyri does not correlate with the degree of human immunodeficiency virus- associated dementia. Acta Neuropathol. 1994;88(6):538-44.
  • 79. Schreiner B, Voss J, Wischhusen J, Dombrowski Y, Steinle A, Lochmuller H, Dalakas M, Melms A, Wiendl H. Expression of toll-like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates IL-8 release and up-regulation of NKG2D-ligands. FASEB J. 2006;20(1):118-20.
  • 80. Dousset V, Armand JP, Lacoste D, Mieze S, Letenneur L, Dartigues JF, Caill JM. Magnetization transfer study of HIV encephalitis and progressive multifocal leukoencephalopathy. Groupe d’Epidemiologie Clinique du SIDA en Aquitaine. AJNR Am J Neuroradiol. 1997;18(5):895-901.
  • 81. Yiannoutsos CT, Nakas CT, Navia BA, Proton MRS Consortium. Assessing multiple-group diagnostic problems with multi-dimensional receiver operating characteristic surfaces: application to proton MR Spectroscopy (MRS) in HIV-related neurological injury. Neuroimage. 2008;40(1):248-55.
  • 82. Ernst T, Chang L. Arnold S Increased glial metabolites predict increased working memory network activation in HIV brain injury. Neuroimage. 2003;19(4):1686-93.
  • 83. Chang L, Ernst T, Leonido-Yee M, Walot I, Singer E. Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex. Neurology. 1999;52(1):100-8.
  • 84. Bossi P, Dupin N, Coutellier A, Bricaire F, Lubetzki C, Katlama C, Calvez V. The level of human immunodeficiency virus (HIV) type 1 RNA in cerebrospinal fluid as a marker of HIV encephalitis. Clin Infect Dis. 1998;26(5):1072-3.
  • 85. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol. 2005;4(9):543-55.
  • 86. Heaton RK, Franklin DR, Ellis RJ, JA MC, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, JC MA, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, CHARTER Group, HNRC Group. HIV- associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17(1):3-16.
  • 87. Estrada-Bellmann I, Camara-Lemarroy CR, Flores-Cantu H, Calderon-Hernandez HJ, Villareal-Velazquez HJ. Hemichorea in a patient with HIV-associated central nervous system histoplasmosis. Int J STD AIDS. 2016;27(1):75-7.
  • 88. Rabhi S, Amrani K, Maaroufi M, Khammar Z, Khibri H, Ouazzani M, Berrady R, Tizniti S, Messouak O, Belahsen F, Bono W. Hemichorea-hemiballismus as an initial manifestation in a Moroccan patient with acquired immunodeficiency syndrome and toxoplasma infection: a case report and review of the literature. Pan Afr Med J. 2011;10:9.
  • 89. Williams DW et al. Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV associated neurocognitive disorders. Curr HIV Res. 2014;12(2):85-96.
Found a mistake? Please highlight the word and press Shift + Enter  
< Prev   CONTENTS   Next >
Business & Finance
Computer Science
Language & Literature
Political science